US Patent

US11696919 — Topical composition

Formulation · Assigned to MC2 Therapeutics Ltd · Expires 2039-03-18 · 13y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a topical composition containing calcipotriol, betamethasone dipropionate, alpha-tocopherol, and butylated hydroxyanisole in a specific pH range.

USPTO Abstract

The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase,wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, andwherein the composition has a pH of 7.75±0.5.

Drugs covered by this patent

Patent Metadata

Patent number
US11696919
Jurisdiction
US
Classification
Formulation
Expires
2039-03-18
Drug substance claim
No
Drug product claim
Yes
Assignee
MC2 Therapeutics Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.